Cargando…
LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis
Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discover...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077312/ https://www.ncbi.nlm.nih.gov/pubmed/35051616 http://dx.doi.org/10.1016/j.ymthe.2022.01.003 |
_version_ | 1784702094489419776 |
---|---|
author | Shi, Linjun Yang, Yuquan Li, Mengying Li, Chenxi Zhou, Zengtong Tang, Guoyao Wu, Lan Yao, Yilin Shen, Xuemin Hou, Zhaoyuan Jia, Hao |
author_facet | Shi, Linjun Yang, Yuquan Li, Mengying Li, Chenxi Zhou, Zengtong Tang, Guoyao Wu, Lan Yao, Yilin Shen, Xuemin Hou, Zhaoyuan Jia, Hao |
author_sort | Shi, Linjun |
collection | PubMed |
description | Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC. |
format | Online Article Text |
id | pubmed-9077312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-90773122023-04-06 LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis Shi, Linjun Yang, Yuquan Li, Mengying Li, Chenxi Zhou, Zengtong Tang, Guoyao Wu, Lan Yao, Yilin Shen, Xuemin Hou, Zhaoyuan Jia, Hao Mol Ther Original Article Oral squamous cell carcinoma (OSCC), which is typically preceded by oral leukoplakia (OL), is a common malignancy with poor prognosis. However, the signaling molecules governing this progression remain to be defined. Based on microarray analysis of genes expressed in OL and OSCC samples, we discovered that the long non-coding RNA IFITM4P was highly expressed in OSCC, and ectopic expression or knockdown of IFITM4P resulted in increased or decreased cell proliferation in vitro and in xenografted tumors, respectively. Mechanistically, in the cytoplasm IFITM4P acted as a scaffold to facilitate recruiting SASH1 to bind and phosphorylate TAK1 (Thr187), and in turn to increase the phosphorylation of nuclear factor κB (Ser536) and concomitant induction of PD-L1 expression, resulting in activation of an immunosuppressive program that allows OL cells to escape anti-cancer immunity in cytoplasm. In nucleus, IFITM4P reduced Pten transcription by enhancing the binding of KDM5A to the Pten promoter, thereby upregulating PD-L1 in OL cells. Moreover, mice bearing tumors with high IFITM4P expression had notable therapeutic sensitivity to PD-1 monoclonal antibody (mAb) treatment. Collectively, these data demonstrate that IFITM4P may serve as a new therapeutic target in blockage of oral carcinogenesis, and PD-1 mAb can be an effective reagent to treat OSCC. American Society of Gene & Cell Therapy 2022-04-06 2022-01-17 /pmc/articles/PMC9077312/ /pubmed/35051616 http://dx.doi.org/10.1016/j.ymthe.2022.01.003 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Shi, Linjun Yang, Yuquan Li, Mengying Li, Chenxi Zhou, Zengtong Tang, Guoyao Wu, Lan Yao, Yilin Shen, Xuemin Hou, Zhaoyuan Jia, Hao LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title | LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title_full | LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title_fullStr | LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title_full_unstemmed | LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title_short | LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis |
title_sort | lncrna ifitm4p promotes immune escape by up-regulating pd-l1 via dual mechanism in oral carcinogenesis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077312/ https://www.ncbi.nlm.nih.gov/pubmed/35051616 http://dx.doi.org/10.1016/j.ymthe.2022.01.003 |
work_keys_str_mv | AT shilinjun lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT yangyuquan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT limengying lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT lichenxi lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT zhouzengtong lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT tangguoyao lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT wulan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT yaoyilin lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT shenxuemin lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT houzhaoyuan lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis AT jiahao lncrnaifitm4ppromotesimmuneescapebyupregulatingpdl1viadualmechanisminoralcarcinogenesis |